Filing Details
- Accession Number:
- 0001415889-18-000013
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-04 18:23:34
- Reporting Period:
- 2018-01-02
- Accepted Time:
- 2018-01-04 18:23:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1365619 | Laura Brege | 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-01-02 | 15,000 | $8.06 | 15,000 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2018-01-02 | 10,000 | $8.49 | 25,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-01-02 | 25,000 | $30.06 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2018-01-02 | 15,000 | $0.00 | 15,000 | $8.06 |
| Common Stock | Stock option (right to buy) | Disposition | 2018-01-02 | 10,000 | $0.00 | 10,000 | $8.49 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-04-30 | No | 4 | M | Direct | |
| 0 | 2018-06-12 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in October 2017.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of May 1, 2008.
- 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.
Billionaire Hedge Funds
